New protein arginine N-methyltransferase 5 (PRMT5) inhibitors are detailed in a Scinnohub Pharmaceutical Co. Ltd. patent and described as potentially useful for the treatment of cancer.

Tango Therapeutics, Inc.’s TNGX share price has dipped by 10.25%, which has investors questioning if this is right time to ...

Scientists at Jiangsu Hengrui Medicine Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have synthesized protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the ...

Bayer and Suzhou Puhe BioPharma Co.,Ltd., a clinical-stage biotechnology company, announced that they have entered into a global license agreement for Puhe BioPharma’s oral, small molecule PRMT5 ...

Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel therapies that address emerging targets in oncology, today announced it will present preclinical ...

The companies have collaborated for Suzhou Puhe BioPharma’s oral, small molecule protein arginine N-methyltransferase 5 (PRMT5) inhibitor that selectively targets methylthioadenosine ...

Under the agreement, Bayer obtains an exclusive worldwide license to develop, manufacture and commercialize the MTA-cooperative PRMT5 inhibitor. Bayer has enrolled the first participant in a Phase ...